“Avexima” Pharmaceutical Company and the national pharmaceutical distributor, the Pharmaceutical Company “FC Grand Capital” will more than double their investments in the Greater Moscow Area

09.12.2021

On December 9, 2021, the “Avexima”, OJSC, Pharmaceutical Company, and the Moscow Oblast Development Corporation, JSC, signed an additional agreement on expanding cooperation within the framework of an investment project for the construction of a pharmaceutical production and logistics complex in the Moscow Oblast in the Esipovo Industrial Park. The project partner is the national pharmaceutical distributor of the Pharmaceutical Company “FC Grand Capital”.

Ekaterina Zinovieva, the Minister of Investments, Industry and Science of the Moscow Oblast, said, “As part of the signed document, the land area for the implementation of the investment project of Avexima company will be increased from 20 to 33 hectares. This will allow the investor to expand the project, which will be implemented in two stages. Investments in the implementation of the project will be increased from 3 to 6.5 billion rubles, and the number of jobs will increase from 1,000 to 1,450 people.”

The Pharmaceutical Company “Avexima”, founded in 2011, is one of the largest manufacturers of active pharmaceutical ingredients and finished medicines in Russia. The company already produces over 140 million packages of finished products per year, with a production capacity of over 1 billion packages per year. The company's market share in the segments of produced drugs in Russia is 5.3%.

As part of the investment project of “Avexima” Company, the Esipovo Industrial Park plans to produce solid and soft dosage forms, as well as liquid sterile dosage forms. The organization of a dedicated production of antitumor drugs (cytostatics), β-lactam antibiotics, and biotechnological drugs is also planned.

Vladimir Slipenkin, the General Director of the Moscow Oblast Development Corporation, noted, "The expansion of the investment project for the construction of a pharmaceutical production logistics complex of the “Avexima” Company in the Moscow Oblast will strengthen the region's position as an attractive investment site with a high level of research activities development, the introduction of science-intensive technologies in the field of pharmaceutical development of new drugs, provide significant revenues to the regional budget, create highly qualified jobs, which, in turn, will further increase the Moscow Oblast investment potential and localize new industries.”

According to Elena Tkachenko, the CEO of the “Avexima”, OJSC, “The construction of a new state-of-the-art pharmaceutical facility in the Greater Moscow Area is of utmost importance for the “Avexima” Company. Already today, in the Skolkovo Technological Park, the Research and Development Center of the “Avexima” Company is functioning, where our new medicinal products are being developed. But the implementation of the company's further ambitious plans requires the creation of a new modern enterprise equipped with highly efficient equipment and advanced technologies in accordance with the international Good Manufacturing Practice standards. The Moscow Oblast high potential in qualified personnel training to work on modern pharmaceutical equipment shall be important for choosing the location of such a high-tech production. The partnership in the implementation of the project with the pharmaceutical distributor of the federal level, the Pharmaceutical Company “FC Grand Capital”, will allow prompt delivery of drugs manufactured at the “Avexima” production site to patients anywhere in Russia in accordance with the modern requirements of the international Good Manufacturing Practice standard.”

“For the Pharmaceutical Company “FC Grand Capital”, the construction of a pharmaceutical production and logistics complex in the Esipovo Industrial Park is a real step in the national drug supply program implementation in Russia.

The advanced technologies in the field of logistics, existing at the pharmaceutical distributor, the Pharmaceutical Company “FC Grand Capital”, will allow to provide a wide range of products consistently from various manufacturers in any region of the country, and using unique monitoring systems to carry out prompt delivery of medicines, preventing their shortage, which will reduce the risk emergence of social tension in the regions.

The implementation of the project will make a significant contribution to the development of pharmaceutical manufacturers, which, on the basis of the production facilities of the "Avexima" Company in the Esipovo Industrial Park, will receive both a modern site for contract manufacturing, and priority advantages in the formation of the distributor's assortment matrix and advanced marketing promotion programs implemented today at the Pharmaceutical Company “FC Grand Capital,” Denis Remenyako, the CEO of the Pharmaceutical Company “FC Grand Capital” commented.

***************************

“Avexima”, OJSC, https://avexima.ru/ - the Russian full-cycle pharmaceutical company operating in three main areas: development, production and promotion of medicines. The production of own medicines is carried out at the production sites of two large Russian pharmaceutical enterprises with a long history: the “Avexima Siberia”, LLC, and the Irbit Chemical and Pharmaceutical Plant (ICPP), OJSC, as well as at the “Immafarma” enterprise in Moscow. These are among the few enterprises that have preserved the technologies of complex synthesis of Russian-produced pharmaceutical substances that meet GMP requirements and ensure the country's pharmaceutical independence.

The range of finished dosage forms of the pharmaceutical products includes drugs for the treatment of gynecological, urological, cardiovascular, neurological diseases, diseases of the gastrointestinal tract, musculoskeletal system, as well as antimicrobial drugs, vitamins, colds and analgesics. The company is constantly expanding its product portfolio with modern and in-demand medicines.

The Pharmaceutical Company “FC Grand Capital”, LLC, https://grand-capital.ru/ is among the top five pharmaceutical distributors of the federal level in the Russian Federation and ranks 171 in the published rating of the 500 largest players in Russian business according to RBC in 2020, and has also been on the list of the TOP 50 fastest growing companies in Russia for several years in a row.

The Company's portfolio includes more than 8,000 products from 400 leading Russian and foreign manufacturing companies. There are more than 48,000 outlets among the clients: from large pharmacy chains to small pharmacies within walking distance.

The total area of the company's warehouse space, equipped with modern equipment and vehicles, is over 60,000 square meters.

The logistics complexes are located in cities such as Moscow, Vladivostok, Volgograd, Voronezh, Yekaterinburg, Kaliningrad, Kirov, Krasnodar, Krasnoyarsk, Novosibirsk, St. Petersburg, Smolensk, Tyumen, and Cheboksary.

The Pharmaceutical Company “FC Grand Capital”, LLC, was founded in Moscow in 2002.

The Moscow Oblast Development Corporation, JSC, http://www.mosregco.ru/ was established on the basis of the Government of Moscow Oblast Resolution dated July 24, 2012 in order to increase the Moscow Oblast investment attractiveness, to facilitate the investment projects implementation, to stimulate the investment activity, and to develop the industrial districts infrastructure. The only Mercedes-Benz Plant in Russia is located on the territory of the Esipovo Industrial Park. The Esipovo Industrial Park managing company is the Moscow Oblast Development Corporation.

The Esipovo Industrial Park is located 35 kilometers from Moscow in the Solnechnogorsky District of the Moscow Oblast. The Park total area is 284 hectares. The M10 highway, which connects Moscow and St. Petersburg, is in the immediate vicinity.